Briacell Therap (NASDAQ:BCTX) Short Interest Update

Briacell Therap (NASDAQ:BCTX) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totaling 282,815 shares, an increase of 94.0% from the March 15th total of 145,756 shares. Based on an average daily trading volume, of 203,382 shares, the days-to-cover ratio is currently 1.4 days. Approximately 3.9% of the shares of the company are sold short.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new stake in shares of Briacell Therap (NASDAQ:BCTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned 0.21% of Briacell Therap as of its most recent filing with the Securities and Exchange Commission. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

Briacell Therap Stock Performance

NASDAQ:BCTX opened at $4.28 on Monday. The stock has a fifty day moving average price of $4.13 and a 200-day moving average price of $7.55. The company has a market cap of $31.03 million, a price-to-earnings ratio of -0.18 and a beta of 1.30. Briacell Therap has a fifty-two week low of $3.60 and a fifty-two week high of $98.20.

Briacell Therap (NASDAQ:BCTX) last released its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter. Research analysts predict that Briacell Therap will post -2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on BCTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. Wall Street Zen lowered Briacell Therap from a “sell” rating to a “strong sell” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.